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Background: Insufficient data are avaüable about the
safety of oral anticoagulant therapy The speciahzed or-
ganization of thrombosis Services m the Netherlands can
provide important Information on the bleedmg risk and
various nsk factors for bleedmg in patients receiving oral
anticoagulant therapy
Methods: In a follow-up study over a 12-month penod
beginmng m January 1988 on all patients treated by the
Leiden Thrombosis Service, the frequency of bleedmg com-
plications was assessed A Poisson regression model was
used to assess the relative contribution to the bleedmg
nsk of age, sex, target zone (intensity of anticoagulant
effect aimed at), achieved intensity of anticoagulant ther-
apy (International Normahzed Ratio), and the type of cou-
marm derivative used
Results: Six thousand eight hundred fourteen patients ex-
penenced 1003 bleedmg complications (16 5 per 100
treatment-years), 162ofwhichweremajorbleeds(2 7 per
100 treatment-years) Bleedmg mcreased sigmficantly with
age (32% mcrease for all bleedmg, 46% for major bleedmg
for every 10-year mcrease m age in companson with age
<40 years) Women had more mmor bleedmg complica-
tions than men, whereas both sexes expenenced major bleed-
mg in an equal frequency There was no influence of target
zone, while every one pomt mcrease m International Nor-
mahzed Ratio gave 42% more major bleedmg (54% more
regardmg all bleedmg) Use of acenocoumarol resulted m
fewer bleeds (26% less regardmg all bleedmg and 46% less
regardmg major bleedmg) than use of phenprocoumon
Conclusions: The risk of anticoagulant therapy m a rou-
tme, real-life Situation is similar äs m the settmg of sev-
eral well-organized clmical tnals The risk of bleedmg com-
plications nses sigmficantly with age and with the achieved
intensity of anticoagulation, and is dependent on the type
of coumarm denvative that is used
(Arch Intern Med 1993,153 1557-1562)
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A LTHOUGH COUMAR1N deriv-atives have been used forseveral decades, there stillis no general agreementabout the mdications for
this therapy ' The most important cause
of this disagreement is a lack of good clm-
ical studies concermng the efficacy and safety
of coumanns in vanous diseases Also, for
a long time the intensity of anticoagula-
tion could not be expressed m unambig-
uous terms Only after the development of
the International Normahzed Ratio (INR)
äs the uniform scale to express the inten-
sity of anticoagulation has it become pos-
sible to target at the same therapeutic ranges
while usmg different prothrombin time re-
agents 2 In many places the Implementa-
tion of oral anticoagulation is hampered by
the lack of the required mfrastructure Ad-
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equate and safe anticoagulation depends
on good patient comphance, accurate lab-
oratory testmg, and adequate dosage reg-
ulation This purpose requires a special-
ized organization 3 In the Netherlands, this
task is performed by a network of throm-
bosis Services whose areas of care cover over
90% of the Dutch population 3 4 It was the
purpose of this study to assess the safety of
the anticoagulation therapy äs supervised
by one of these Services To this end, we per-
formed a follow-up study among the patients
of the Leiden Thrombosis Service
See Subjects and Methods
on next page
SUBJECTS AND METHODS
THE LEIDEN THROMBOSIS SERVICE
The Leiden Thrombosis Service functions like all Dutch throm-
bosis Services.3·4 It takes care of the control of treatment with
coumann derivatives for all outpatients m the region of Leiden,
the Netherlands. The area has about 460 000 inhabitants and
four hospitals. The medical staffs of the mdividual hospitals take
care of in-hospital anticoagulant therapy. After discharge, pa-
tients are referred to the thrombosis Service for the control of
outpatient anticoagulant therapy. A specialized System of oral
anticoagulant monitoring has been developed.3 In this special-
ized System, nurses who are specially trained in anticoagulant
therapy control play a central role. They collect blood samples
of the patients at several outpatient facilities in Leiden and sur-
rounding villages. When necessary, patients are visited at home.
With every venipuncture, a standardized short history is taken
about bleedmg complications, changes in comedication, mter-
current illnesses, and surgical procedures. Each new patient re-
ceives extensive mstructions about anticoagulant therapy. Sub-
sequently, prothrombm times are assessed at the thrombosis
Service, where a team of speciahzed physicians determmes the
dosage and the control period, which is dependent on the sta-
bility of the anticoagulant level. The control period varies from
l to 6 weeks, with an average of 3.3 weeks. The dosage is printed
on a dosage list that the patient receives by mau the next day.
In case of bleeding complications or excessive intensity of the
anticoagulant effect, the patient is telephoned the same day for
dose adjustment or administration of vitamin K. The Leiden
Thrombosis Service has been treatmg patients in this way for
more than 30 years. All administrative data, test results, dosage
lists, äs well äs the dosage determination have been comput-
enzed since 1973. In fifty-five percent of all checks, an auto-
matic dose prescription is generated Details of this dosage al-
gorithm have been descnbed previously.5
DATA COLLECTION AND ANALYSIS
All patients under treatment at the Leiden Thrombosis Service
onjanuary l, 1988, were selected from the Computer files. From
these patients, the following items were abstracted from the Com-
puter files: Identification number, date of birth, sex, mdication
for anticoagulant therapy, coumarin derivative used (either phen-
procoumon or acenocoumarol), target ränge, all prothrombin
times, all doses prescribed, and, if applicable all bleedmg com-
plications, hospital admissions, death and cause of death, and
reasons to stop treatment durtng the year 1988. The indica-
tions and the target ranges (intensity of anticoagulant effect aimed
at) of anticoagulant therapy are listed in Table 1. The study
population was subdivided into patients who received antico-
agulant therapy for prevention of arterial thrombotic disease
and patients with any other indication.
Bleeding complications were subdivided into major and
minor bleeding. Major bleeding was defined äs intracranial hem-
orrhage, bleeding that caused death, bleeding that required blood
transfusion, admission to a hospital, or surgery, äs well äs all
muscle and joint bleeding. Minor bleedmg included all other
bleeding complications. In case of doubt, any bleeding was coded
äs major bleeding. When it was possible but not certain that
a patient died of a bleeding complication, this death was coded
äs caused by bleedmg.
LABORATORY INVESTIGATION
Venous blood was collected in 1/10 volumeofO.il mol/Ltri-
sodium citrate, and prothrombin times were determined usmg
the Thrombotest reagent (Nyegaard, Oslo, Norway). This pro-
thrombin time reagent was specifically devised for the control
of oral anticoagulant therapy6 and is widely used by the throm-
bosis centers in the Netherlands. Results are expressed m INR.2
Incidence rates of bleeding complications were calculated
in the Standard way, by dividing the number of events by the
number of treatment-years. To study the independent contn-
bution to the bleeding nsk of the putative risk factors age, sex,
target zone, achieved level of intensity of anticoagulation, and
type of coumann drug, we set up a Poisson regression model.
The incidence rate ratlos derived from this regression analysis
may be viewed äs relative nsks, le, the nsk of bleeding relative
to the reference risk factor category. The reference categories were
arbitrarily set at age under 40 years, male sex, low target zone,
achieved INR below 2, and phenprocoumon use. The variables
were first categorized in a limited number of classes and sub-
sequently entered into the model m an unfactored way. The in-
cidence rate ratios were calculated for each 10 years' increase in
age, female sex, each increase m target zone, eachincrease of l
INR, and acenocoumarol use. In the Poisson regression model,
we analyzed six INR zones ranging from INR below 2 to INR
of 6 or greater, with an mcrement of 1.0 INR per zone. For age,
five groups were analyzed ranging from age 39 years and lower
to age greater than 69 years, with an increment of 10 years per
group. For each age group, each type of coumarin used, each
sex, every target zone, and each INR zone, the following items
were counted: the number of complications regarding all bleed-
ing and maj or bleeding separately and the number of days spent
within the particular INR zone. Foi this last item, from every
INR half the control period before and half the control penod
afterward was taken (example, an INR was assessed at Apnl l,
May l, and May 15. The number of days spent within the INR
of May l [22 days] is calculated by summing half the number
of days between Apnl l and May l [ 15 days] and between May
l and May 15 [7 days]). This method has been descnbed ex-
tensively elsewhere.7 For each patient, the observation started
onjanuary l, 1988,andendedonDecember31,1988,orwhen
the first compkcation took place, or when treatment was stopped
for any other reason.
The proportion of time the patients spent with their
INR within the target ränge was assessed using the "cross-
section-of-the-files" method.4 In this method, an arbitrary
date is chosen. From all the patients, the INR at this date or
the last INR before this date is taken. Subsequently, the per-
centage of INRs within the target ränge is assessed. Because
the date was chosen arbitranly and because a high number
of patients is mvolved, the percentage of INRs within the
target ränge is a reflection of the proportion of time the pa-
tients spent with their INR within the target ränge.
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RESULTS
The Figure shows the distnbution of patients, subdi-
vided accordmg to sex, over the vanous mdications for
anticoagulant treatment Most patients, especially men,
were treated for prevention of arterial thrombotic disease
In Table 2, the number of patients, the number of
treatment-years, age, and the type of coumarm used are
presented subdivided to mdication for anticoagulant treat-
ment (prevention of artenal thrombotic disease in com-
panson with any other mdication) and subdivided to sex
The percentage of INRs withm the target ränge (cross-
section-of-the-files method) was 77
The total number of bleeding episodes was 1003, or
16 5 per 100 treatment-years (Table 3) Major bleeding
occurred 2 7 times per 100 treatment-years, and in 39
cases bleeding resulted m death (0 64 per 100 treatment-
years) The most frequent major bleeding complications
were bleeding from the gastromtestmal tract, mtracramal
bleeding, and muscle bleeding Intracramal bleeding was
the most frequent cause of bleeding-related death (22
cases) In mne (5 5%) of 162 cases (three men and six
women), the bleeding comphcation was coded äs major
while there was no absolute certamty about this classifi-
cation Eight of these patients died outside a hospital, and
their general practitioners reported mtracramal bleeding
äs the cause of death without a computed tomographic
scan or autopsy to confirm this diagnosis One patient
was admitted to a hospital reportedly because of a severe
hematoma
To establish the mdependent mfluence of vanous pos-
sible nsk factors for the occurrence of bleeding (age, sex,
target zone, coumarm derivative used, and the achieved
mtensity of anticoagulation or INR), we performed a Pois-
son regression analysis, the results of which are given m
Table 4 For all bleeding äs well äs major bleeding, there
was a significant mcrease m complications with age in
companson with the age group of less than 40 years, ev~
ery 10 years' mcrease of age was associated with 32% more
bleeding and 46% more major bleeding Women ap-
peared to have more complications when all bleeding was
considered For major bleeding, the sex difference dis-
appeared For both major and all bleeding, there was less
bleeding when the short-actmg acenocoumarol is used in
companson with phenprocoumon Bleeding frequency seems
to become lower when a more intensive level of antico-
agulation is targeted (mcreasmg target zone) When not
the targeted but the achieved level of anticoagulation is
analyzed, bleeding nses significantly (major and all bleed
4
'tag) with mcreasmg INR
In Table S the bleeding complications per 100 treat-
jnent-years are given for each of six achieved INR levels
For men and women ahke, a clear nse m bleeding com-
plications can be seen for mcreasmg intensities of anti-
'Coagulation
Table 1. Indications and Target Ranges
for Oral Anticoagulant Treatment*
Prophylaxis of venous thromboembolism (INR, 2 4-2 9-3 7)
Postoperatively
Immobihzation
Heart failure
Treatment of venous thromboembolism (INR, 2 8-3 5-4 8)
Superficial thrombophlebitis
Deep vem thrombosis
Pulmonary embohsm
Prevention of arterial thrombotic disease (INR, 2 8-3 5-4 8)
Myocardial mfarction (long term)
Angina pectons
Coronary bypass surgery and PTCA
Penpheral arterial disease and surgery
Cerebrovascular disease
Prevention of arterial embohsm (INR, 2 8-3 5-4 8)
Atnal fibnllation
Artenal embohsm
Cardiomyopathy
Heart valve disease
Prosthetic heart valves (INR, 3 2-4 0-5 3)
*INR mdicates International Normalaed Ratio, PTCA percutaneous
transluminal coronary angioplasty
COMMENT
The results of this study are a reflection of normal daily
practice of the Leiden Thrombosis Service Smce all data
are routmely stored in the Computer and because the Leiden
Thrombosis Service has a regional task, U is unhkely that
bias occurred
Six thousand eight hundred four patients were treated
by the Leiden Thrombosis Service m 1988 The catch-
ment area of this Service is about 460 000 persons There -
fore, one of every 66 persons was treated in our center
Most patients, especially men, are under treatment for the
prevention of artenal thrombotic disease (Figure and Ta-
ble 2) This group consists mamly of patients who suffer
from atherosclerotic disease myocardial mfarction or pe-
ripheral arterial disease (Table 1) Traditionally, many of
our patients with artenosclerotic disease are treated with
coumarm derivatives This is due partly to the existence
of the System of the Dutch thrombosis Services3 and partly
to the results of the Sixty Plus Remfarction Study8 As
mdicated above, these semces offer the optimal mfra-
structure for anticoagulant therapy
Bleedmg complications (Table 3) were less frequent
m patients with artenal thrombotic disease than m pa-
tients with other mdications for anticoagulant treatment
This is true for men and women and for all the vanous
subdivisions of complications we mvestigated Patient se-
lection bias cannot be excluded äs an explanation for this
phenomenon Patients with artenal thrombotic disease usu-
ally are takmg long-term anticoagulant therapy and pa-
ARCH INTERN MED/VOL 153 JULY 12 1993
1559
tients at high risk for bleedmg may have stopped anti-
coagulant therapy m the past This does not apply to the
other mdicaüon group with many patients takmg short-
teirn anticoagulant therapy
The figures on bleedmg complications m our study
(Table 3) are similar to the results of the Sixty Plus Re-
mfarction Study9 The total bleedmg rate of 16 6 per 100
treatment-years in this prospective, double-blmd mal is
simüar to the frequency of 16 5 per 100 treatment-years
that we found In the Sixty Plus Remfarcnon Study, ma-
jor bleedmg occurred at a rate of 5 15 per 100 treatment-
years, while six patients died of a bleedmg complication
(0 86 per 100 treatment-years) In the Sixty Plus Rem-
farction Study, however, the defmition of a major bleed-
mg complication was different from our defmition any
bleed that made breakmg the treatment code necessary
We think that this explams the twofold difference in ma-
jor bleedmg complications that was found, while the oc-
currence of total bleedmg and fatal bleedmg is the same
Lower mcidences of major bleedmg were found m
the recent Norwegian warfarm remfarction study (0 86
per 100 treatment-years) and in two recent tnals on the
effect of warfann on the prevention of artenal embolism
in patients with nonrheumatic atnal fibnllation 1012 In diese
three studies there are important differences from our study
regardmg the defmition of bleedmg complications, pa-
tient selection, and target mtensity of anticoagulant ther-
apy In three retrospective studies,131S a higher frequency
of bleedmg was found, while the results of three other
studies are simüar 1618 The problem of different defmi-
tions of complications m these studies is difficult to solve
Our data mdicate that anticoagulation äs supervised m
the daüy settmg of our thrombosis service is no less safe
than it was m the settmg of a randomized clmical tnal
hke the Sixty Plus Remfarction Study9
Lookmg for nsk factors for bleedmg complications,
we evaluated age, sex, target ränge, the achieved level of
mtensity of anticoagulation, and the type of coumann de-
rivative usmg a Poisson regression model (Table 4) The
regression analysis äs given in this table was performed
4000η
3000-
o- 2000-
1000-
INR,
28-48
Prophylaxis Treatment Prevention Prevention Prosthetic
of Artenal of Artenal Heart
Venous Thrombotic Embolism Valves
Thromboembolism Disease
Patient distribution according to treatment mdication groups and
subdivided according to sex See Table 1 for the composition of the
mdicat/on groups For each group, the target level of mtensity of oral
anticoagulation is mdicated in International Normalized Ratio (INR) (closed
bars mdicate men, shaded bars, women)
without subdividmg according to mdication for antico-
agulant therapy When such a subdivision was made, how-
ever, the results were exactly the same As can be ex-
pected from the data m Table 3, patients with mdications
other than artenal thrombotic disease had a higher nsk of
bleedmg This was true for all bleedmg (rate ratio, l 24,
95% confidence hmits, l 07, l 43) äs well for major bleed-
mg (rate ratio, l 66, 95% confidence Imiits, l 20, 2 31)
Women appear to have more bleedmg than men when all
bleedmg is considered, but not when major bleedmg is
considered Until now, no difference in bleedmg fre-
quency between men and women has been reported in
the literature913161Θ We found a sigmficant mcrease with
age for mmor äs well äs major bleedmg In comparison
with the age group of less than 40 years, every 10 years'
muease m age was associated with 32% more bleedmg
and 46% more major bleedmg In most studies, age was
not found to be a nsk factor,9 °141617 while m others this
was the case 1518 A possible explanation for this differ-
Table 2. Characteristics
,
No. of sub|ccts
No of treatment years
Age, y
Mean,
Mediän
Range
Coumarin derivative uscd
Phcnprocoumon
AcRRocoumarol
of the Study Population
Arterial
Disease
3511
3268
64
64
23-94
3079
432
Men
Other
Indications
1106
926
65
67
16-95
976
130
1
Total
4617
4194
64
65
16-95
4055
562
Arterial
Disease
1103
1004
68
70
24-96
974
129
Women
Other
Indications
1094
887
68
72
5-95
9?8
166
l
Total
2197
1891
68
70
5-96
1902
295
l
Arterial
Disease
4614
4272 ·
65
65
23-96
4053
561
Total
Other
Indications
2200
1813
68
69
5-95
1904
296
l
Total
6814
6085
66
62
5-96
5957
857
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Table 3. Observed
All Bleedlng
Mmor bleedmg
Major bleedmg
t Intracranial
Digestive tract
Muscle |omt
hematoma
Other
Fatal bleedmg
Bleeding Complications
1
1
Arterial
Disease
398(122)
332(102)
6&(20)
13(040)
27 (0 83)
13(040)
13(040)
12(037)
Men
Other
Indications
157(169)
122(132)
35 (3 8)
10(11)
12(13)
5 (0 54)
8 (0 86)
14(15)
Mo.
1
- Total
555 (13 2)
454(108)
101(24)
23 (0 55)
39 (0 93)
18(043)
21 (0 50)
26 (0 62)
(per 100 Treatment-Years) of Complications in
l
Arterial
Disease
222(221)
196(195)
26 (2 6)
7 (0 70)
8 (0 80)
7 (0 70)
4 (0 40)
6 (0 60)
Women
Other
Indications
226 (25 5)
191 (21 5)
35 (4 0)
8 (0 90)
11 (1 2)
6 (0 68)
10(11)
7 (0 79)
l
Total
448 (23 7)
387 (20 5)
61 (3 2)
15(079)
19 (1 00)
13 (0 69)
14 (0 74)
13 (0 68)
l
Arterial
Disease
620(145)
528(124)
92 (2 2)
20 (0 47)
35 (0 82)
20 (0 47)
17 (0 40)
18 (0 42)
Total
Other
Indications
383(21 1)
313(173)
70 (3 9)
18 (0 99)
23 (1 3)
11(061)
18(099)
21 (1 2)
1
1
Total
1003(165)
841(138)
162(27)
38 (0 62)
58 (0 95)
31(051)
35 (0 58)
39 (0 64)
ence with most of the hterature is that we had a large
group of patients of older age Besides, the most stnkmg
nse m bleedmg rate was found in patients above the age
of 70 years
We did not find an mcrease m bleeding, either to-
tal or major, with mueasmg target zones This result
was to be expected m the multivanate Poisson analysis,
m which we adjusted for the achieved intensity of an-
ticoagulation To our surpnse, however, we also ob-
served no effect of the target zones m the umvariate
analysis, in which the achieved level was not taken
mto account (data not shown) This is in contrast with
the hterature, where generally an mcrease in bleeding
frequency is found l9 B A possible explanation could be
that we were unable to remam at the target level a suf-
ficient length of time However, usmg the cross-
section-of-the-files method, 77% of the INRs were
withm the target ränge, which indicates a good level of
therapeutic quahty Most studies in the literature com-
pare patients with the same mdication for anticoagu-
lant therapy m their target range-dependent bleeding
nsk In our study population there were different mdi-
cations for therapy with coumanns in the vanous tar-
Table 4. Results of Poisson Regression
Rate Ratlos (95% Confidence Limits)*
Age
Sex
Target zone
INR
Coumarm type
All Bleeding
Complications
1 32 (1 22, 1 43)
1 65 (1 44, 1 90)
074(061,090)
1 54 (1 44, 1 65)
0 74 (0 59, 0 94)
Analysis:
Major Bleeding
Complications
1 46 (1 20, 1 78)
116(083,161)
0 57 (0 38, 0 86)
142(1 21,168)
0 54 (0 29, 0 99)
*For age, the rate ratio is presented for each 10 years' mcrease in age
W companson with age younger than 40 years for sex, for women m
companson with men, for target zone, for each nse m target zone in
companson with the Iowest one, for International Normalized Ratio (INR),
for each mcrease m one umt INR m companson with INR below 2, and for
coumann type, for the use of acenocoumarol m companson with
ptienprocoumon
get zones (Table l and Figure) An important factor in
this regard is that in the Iowest target zone (INR, 2 4
to 3 7) more than 80% of the patients with a bleeding
comphcation were classified in this target zone because
of a relative contramdication to anticoagulant therapy
(data not shown) Without this contramdication, they
would have been classified in the middle target zone
(INR, 28 to 48), corresponding to their mdication for
anticoagulant therapy This vulnerable group of pa-
tients has a great influence on the frequency of bleed-
ing in patients in the Iowest target zone This possibly
explams the surpnsmgly negative influence on the
bleeding nsk of mcreasmg target zones When not the
mtended but the achieved level of anticoagulation was
analyzed, a clear nse of bleeding with mcreasmg intensity
was found (Table 4) For all bleeding, we found 54% more
bleeding for every rise of the INR with one point For
major bleeding this figure is 42% These fmdmgs are m
good agreement with the hterature 3 9 1 6 1 9 2 1 2 4 In Table 5,
the number of bleeding Complications m relation to the
achieved level of INR is shown These data are the same
äs m the Poisson regression analysis Presentation m this
way gives another, possibly more informative, view of the
influence of mcreasmg INR on the bleeding frequency
The fourth nsk factor we mvestigated was the use of
Table 5. Observed Bleeding Complications
Treatment-Years With Increasing INR*
INR
<2
2-3
3-4
4-5
5-6
3:6
All
Men
14
8
11
15
26
49
Bleeding
l
Women
9
16
19
25
51
143
per 100
Major Bleeding
ι ι
Men Women
3
2
2
4
5
5
3
3
4
5
13
*II\IR indicates International Normalized Ratio
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different coumarin drugs. We were able to do this study
because both coumarin derivatives (phenprocoumon and
acenocoumarol) were taken by a substantial pari of the
patients. We found almost two times less bleeding when
the short-acting acenocoumarol (half-life, 14 hours) was
used in comparison with the long-acting phenprocou-
mon (half-life, 170 hours). A similar finding was found in
the Sixty Plus Study.9 Possibly, an overintense anticoag-
ulant effect due to phenprocoumon will last longer and
thus may lead to more bleeding. Our study is limited in
this regard, however. The choice between the use of aceno-
coumarol or phenprocoumon is made by the referring spe-
cialist, who Starts the treatment on the basis of his or her
preference. In general there is a preference in our region
for the use of the long-acting phenprocoumon because a
more stable anticoagulation level can be achieved. Fur-
ther investigation clearly is necessary on this point. It is
too early to draw therapeutic consequences from this find-
ing because efficacy data are required to compare the bal-
ance of efficacy and bleeding for the two drugs. Whether
there is a different bleeding frequency with the use of war-
farin is an open question at this moment, because no com-
parative data are available on this derivative.
In conclusion, our data provide Information on the
risks of anticoagulant therapy in a routine, real-life Situ-
ation äs opposed to the setting of well-organized clinical
trials. Important findings are the increase of bleeding com-
plications with increasing age and the dependence of bleed-
ing frequency on the type of coumarin derivative used.
Accepted for publication December l, 1992.
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